Melanoma incidence is growing at a faster rate than any other human malignancy. Wild -type ( wt ) p53 is important in both G 1 and G 2 cell cycle arrest, and cyclin D1 ( CD1 ) is necessary for G 1 !S progression in melanoma cells. We reported that an adenoviral vector containing wt p53 significantly reduced [ 3 H ]thymidine uptake in melanoma cells containing mutant but not wt p53. Subsequently we showed that CD1 decreased melanoma proliferation and increased apoptosis. We now extend these findings by evaluating the effect on preformed melanomas of ( 1 ) intratumoral therapy with wt p53 alone, ( 2 ) wt p53 in combination with antisense ( AS ) CD1, both short ( 14 days ) and longer term, and ( 3 ) doubling the dose or repeat doses of wt p53 or AS CD1. Two melanoma cells lines that metastasize in SCID mice ( 451 and 1205 ) were used, one containing a p53 mutation ( 451 ) and the other a normal p53 gene sequence ( 1205 ). Compared to injection with a control adenoviral vector containing -galactosidase ( LacZ ), intratumoral injection of wt p53 slowed the growth of tumors formed from 451 cells. Using 5Â10 8 plaque forming units as our standard intratumoral dose, neither doubling the dose of LacZ, p53 or AS CD1, nor repeat doses of the vectors, was as effective as combined therapy with wt p53 + AS CD1, which resulted in the shrinkage of all tumors treated and 4 / 7 ( 57% ) tumors vanished. No tumors treated with wt p53 or AS CD1 alone vanished. Wt p53 + AS CD1 treatment resulted in significantly more cells undergoing apoptosis compared to either therapy alone. In summary, combining the separately effective treatment vectors p53 and AS CD1 led to an enhanced growth -suppressive and apoptotic effect, supporting a role for combination gene therapy to treat human malignant melanoma.
T he incidence of melanoma has been increasing at a rate of 3% per year since 1981. 1 In 2002, 53,600 persons are expected to be diagnosed with melanoma, and over 7000 of these will die of their disease. Ultraviolet light ( UV ) present in sunlight, especially UV within the B spectrum (29 -to 320 -nm wavelength ) has been implicated as a possible cause for melanoma development. UVB induces characteristic C!T and CC!TT mutations in the p53 gene, 2 and these mutations are seen in both primary melanomas and melanoma cell lines. 3, 4 Although the exact role of p53 in the development of melanoma has been questioned, 5 the association between UV radiation and melanoma is clear. In experimental animal systems, UV either causes or contributes to melanoma development. The South American opossum Monodelphis domestica, which lacks a DNA repair mechanism, develops melanomas at a high rate after approximately 1 year of UV treatment. 6 The administration of 7,12 -dimethylbenz[ a]anthracene ( DMBA ) followed by croton oil and UV leads to melanoma in mouse skin. 7 Administration of UVB to human skin in which bFGF is overexpressed leads to pigmented lesions with highgrade atypia resembling lentiginous forms of malignant melanoma. 8 There is substantial evidence that critical regulatory steps occur during the cell cycle which determine whether or not the cell will synthesize new DNA and divide. These critical regulators of G 1 are frequent targets for mutations. 9 Two important regulators of G 1 are p53 and cyclin D1 (CD1 ). p53 appears to suppress cell division by stimulating the synthesis of the cyclin-dependent kinase (cdk ) inhibitor p21. 10 There is evidence that p21, a universal inhibitor of cdks, plays a role in both G 1 and G 2 arrest.
11 p53 has been implicated in G 2 control in a variety of systems, as demonstrated by the finding that p53 overexpression in p53 -deficient fibroblasts causes both G 1 and G 2 arrest. 12 Several laboratories have found that the G 2 / M checkpoint can be circumvented more readily in p53 -deficient cells than in those with functional p53 protein.
12 p53-mediated suppression is likely a normal cell response to inappropriate initiation of DNA replication.
CD1 is a proto -oncogenic regulator 13 of the G 1 /S checkpoint in the cell cycle that has been implicated in the pathogenesis of several types of cancer. CD1 binds to cdk 4 or 6, leading to phosphorylation of the retinoblastoma protein (pRb ) by the cdk.
14 This phosphorylation inactivates the pRb -mediated inhibition of the E2F family allowing the cell cycle and DNA synthesis to proceed. Induction of melanoma terminal differentiation leads to a decrease in CD1 levels, 15 and microinjection of a CD1 -neutralizing antibody arrests melanoma cells in G 1 whereas p16 does not, 16 suggesting that when pRb is functional, CD1 is required for G 1 progression. Because p53 ( through p21) inhibits a variety of cdks, whereas CD1 primarily binds to cdk 4 and 6, we hypothesized that using adenoviral vectors that contain p53 or CD1 might prove complementary in inhibiting melanoma growth.
We previously reported encouraging in vitro findings with overexpression of wild -type (wt ) p53 in melanoma cell lines containing either normal or mutated p53. 17 Three melanoma cells lines, two that express wt p53 (WM115 and 1205 ) and one (WM164, a line derived from a tumor whose metastasis led to the development of 451 ) that expresses mutant p53, were infected with an adenoviral vector that overexpresses wt p53. Overexpression of wt p53 did not inhibit growth of the cell lines containing wt p53, but did inhibit the line that expresses mutant p53 protein. Our findings suggested that p53 overexpression was effective only in melanomas with mutant p53, which unfortunately comprise only a minority of human melanomas. 17 In a separate report, we documented that antisense (AS ) CD1 led to inhibition of CD1 cell growth in squamous cell carcinomas both in vitro and in vivo. 18 We also observed shrinkage of melanomas after treatment with AS CD1. 19 Treatment of both 451 and 1205 tumors with AS CD1 led to significant growth suppression compared with treatment with the LacZ (control ) vector. Unfortunately, although melanomas shrank after AS CD1 therapy, they did not disappear.
The goal of this report is to explore strategies that would improve the efficacy of our therapy using adenoviralmediated expression of wt p53 and AS CD1 to treat human melanoma. We had three hypotheses: (1 ) intratumoral wt p53 monotherapy would lead to the shrinkage of preformed melanomas, (2 ) therapies that target different points in the cell cycle would be more effective than monotherapy, and treatment response would be prolonged, and ( 3 ) doubling the dose or repeat doses of p53 or AS CD1 would be more efficacious than a given dose of monotherapy. To test our hypotheses, we evaluated adenoviral vectors containing wt p53 and AS CD1. Our findings demonstrate that combination therapy with wt p53+ AS CD1 may be more effective than monotherapy. Neither doubling the viral dose nor sequential doses of a given vector was as effective as combination treatment. Targeting the cell cycle at two different points through interactions with a variety of cdks using vectors that express p53 and AS CD1 appears to provide an efficient strategy for therapy of melanomas.
Methods

Cell culture
Two human melanoma cell lines, 451 ( containing mutant p53 ) and 1205 ( containing wt p53 ), 20 -22 were grown in MCDB 153/L15 (Sigma Chemical, St. Louis, MO ) in a 4:1 ratio supplemented with 5 g/mL insulin with or without 1% FCS (melanoma media ). Both lines, derived from human melanomas, metastasize when injected into immunodeficient mice. Transcomplementing 293 cells, 23 immortalized and transformed by adenovirus E1a and Elb, respectively, were obtained from the Vector Core at the Institute for Human Gene Therapy ( University of Pennsylvania, Philadelphia, PA ) and grown in DMEM supplemented with 10% FCS. All tissue culture reagents were purchased from Sigma.
Construction of replication defective adenoviral vectors
A replication defective (E1 and E3 deleted) adenovirus containing -galactosidase ( LacZ ) was also obtained from the Vector Core. A replication defective ( E1 deleted ) adenovirus containing wt p53 was a gift of Dr Wafik El-Deiry, University of Pennsylvania. The creation of the vector has been previously described. 24 Briefly, a p53 cDNA was cloned and then subcloned into pMV10 and pMV60, respectively. 25 The plasmids pMV60 -p53 -wt and pJM17 25 were cotransfected into 293 cells. Recombinants (p53) were plaque purified and found to produce transcriptionally active p53. The construction of AS CD1 has been previously described in detail elsewhere. 18 Briefly, 20-mer primers designed to amplify CD1 were PCR amplified for 35 cycles. The 1.1 -kb product including the entire CD1 open reading frame was inserted into the adenoviral shuttle vector pAd.CMV-Link.1 ( University of Pennsylvania Vector Core). pAd.CMV-Link1 was then cotransfected into 293 cells with adenoviral DNA lacking the E1 and E3 regions, 26 using calcium phosphate precipitation. Homologous recombination between pAd.CMVl -LINK.1 and dl7001, resulting in the incorporation of CD1 into the adenoviral backbone, led to a cytopathic effect as evidenced by plaque formation after approximately 2 weeks.
Assessment of in vivo transgene expression and tumor growth
451 and 1205 cells were grown in melanoma media to 70-80% confluence, detached with 0.06% trypsin /EDTA, the cells counted, and 10 7 cells injected subcutaneously into the dorsal hindquarter of SCID mice just medial to the right hind limb. After tumors had grown to a minimum volume of 75 mm 3 , one or two viral constructs ( each consisting of 5Â10 8 plaque -forming units [ pfu ] virus in 50 l melanoma media ) were injected within each tumor at baseline using a tuberculin syringe. A second dose of one viral construct was administered 7 days after baseline to a subset of the tumors. Each treatment was administered to four to eight mice. The treatments administered were LacZ, wt p53, LacZ +LacZ, LacZ +wt p53, LacZ +AS CD1, wt p53 +AS CD1, wt p53 +wt p53, and AS CD1 + AS CD1.
To determine whether the transgene entered and was expressed within the tumor cells, mice were sacrificed 2 days after intratumoral injection of either LacZ or wt p53. Each tumor was divided in two parts, one part snap frozen and kept in À 808C and the other placed in neutral buffered formalin for 12-24 hours before embedding in paraffin wax. Sections (7 m ) of frozen tumor tissue were placed onto glass slides, fixed in 0.5% glutaraldehyde, washed in a MgCl 2 solution, X -gal added, and counterstained with hematoxylin.
In similar fashion, 7-m sections of formalin -fixed tumor tissue were deparaffinized in xylene, rehydrated in graded alcohols to water, and treated with methanol /H 2 O 2 . A p53 monoclonal Ab (clone DO -7, DAKO, Carpinteria, CA ) was added for 1 hour, followed by a biotinylated secondary ( DAKO multi -LINK ), 3 0 3 0 -diaminobenzidene, and a counterstain of hematoxylin.
Each tumor was measured five times: at baseline, and 4, 7, 10 and 14 days after viral transduction. If the tumor vanished by day 14, the mice were observed for longer periods to determine if the tumor would return. All mice were sacrificed by day 31. Tumor volumes at these five time points were fitted to y= A exp( t). The tumor regression rate b was thus estimated for each mouse from the five observations. The s in each group of mice were rank ordered and submitted to the Wilcoxon two -sample ( one-sided ) procedure to test the hypothesis of equal rates of tumor regression among groups versus the alternative that treated tumors regress faster.
Apoptosis 451 and 1205 cells were grown to 70 -80% confluence in melanoma media with 1% FCS. 1205 cells were also grown without serum ( 451 cells did not grow well in serum -free media). For cells grown with serum, culture media were removed and serum -free media added before viral transduction. The cells were then mock transduced or transduced with LacZ, wt p53, or a combination of wt p53, AS CD1, and LacZ. We determined, using [ 3 H ]thymidine incorporation, that the optimal in vitro dose ( maximal effect of vector with minimal nonspecific toxicity, as evidenced by inhibition of cell proliferation after treatment with control, a LacZ containing vector ) of p53 and AS CD1 for 451 and 1205 cells was 50 and 100 pfu, respectively ( data not shown ). A viral titer of 50 pfu /vector was used for monotherapy; thus, cells undergoing combined therapy received 100 pfu/cell. Combinations included LacZ + LacZ, LacZ +wt p53, Lac-Z + AS CD1, wt p53 +wt p53, wt p53 + AS CD1, and AS CD1 +AS CD1. Cultured cells were detached 1, 2, 3, 4, and 5 days after transduction with 0.06% trypsin /EDTA and fixed in 70% ethanol. After pelleting and ethanol removal, the cells were resuspended in propidium iodide and left in the dark for a minimum of 20 minutes. Cell cycle analysis, including the sub -G 0 or apoptotic cell fraction, was then determined using an EPICS XL flow cytometer (Coulter, Hialeah, FL ). Linear regression was applied to the 5-day data plots of each trial. A generalized likelihood ratio statistic was then used to compare the rates of cell apoptosis for treatment pairs. This generated a 2 statistic with one degree of freedom. We then applied a Bonferroni adjustment for multiple comparisons to determine significance.
Results
Increased p53 expression after transduction with wt p53 but not LacZ
We previously demonstrated that AS CD1 led to a 78% reduction in CD1 protein expression. 19 We now wanted to determine if transduction of wt p53 and LacZ would lead to cellular uptake and expression of the relevant proteins ( p53 and -galactosidase ). p53 was highly expressed in 1205 tumors after transduction with wt p53 (Fig 1A ) , but not after transduction with LacZ ( Fig 1C ) . Because baseline expression of mutant p53 was high in 451, the increase in expression of wt p53, although present, was not as dramatic as in the case of 1205 (Fig 1, B and D ) , in which baseline expression was low. There was significant expression of -galactosidase after transduction with LacZ (Fig 1, E and F) , which was not observed in the mock -treated tumors ( not shown).
In vivo growth suppression after transduction with wt p53 alone and in combination with AS CD1 Monotherapy, therapy using increased pfu / cell, and sequential therapy. p53 did not significantly delay the growth of formed 1205 tumors compared with LacZ control (Fig 2 ) , whereas tumor growth was significantly delayed in tumors formed from 451 cells (P=.036). All tumors were at least 125 mm 3 in volume.
Because 5Â10 8 pfu of the p53 vector did not shrink 1205 tumors >125 mm 3 , tumors < 125 mm 3 were injected with the tumor using a similar dose ( Fig 2) . Using this strategy, wt p53 significantly slowed the growth of the smaller tumors compared to treatment with LacZ (P=.0079 ). However, doubling the pfu dose of AS CD1 into tumors >125 mm 3 did not significantly improve efficacy. Providing a second intratumoral injection of either p53 or AS CD1 1 week after the first also did not significantly influenced tumor growth.
Combination therapy. We chose 1205 cells as the model for in vivo therapy because they were less responsive than 451 cells to p53 monotherapy, suggesting that either a larger dose of wt p53 or wt p53 plus AS CD1 was needed. Figure 3 illustrates the response of tumors formed from 1205 cells to treatment combinations ( p53 +p53, LacZ +LacZ, AS CD1 +AS CD1, p53+ AS CD1 ). p53+ AS CD1 suppressed 1205 tumor growth compared to LacZ + LacZ ( P= .0025 ) or wt p53 +wt p53 (P=.036 ), but not AS CD1 + AS CD1 ( P= .18 ). Whereas 0/ 10 tumors treated with p53 alone and 0 /11 treated with AS CD1 disappeared, 4/ 7 tumors vanished after combined treatment with wt p53+ AS CD1 (P=.0017). The first tumor vanished 7 days after treatment, and each of the four disappeared by 14 days. The first returned 24 days after treatment, and all had returned by 31 days. Each tumor that returned remained at < 15% of their original size until sacrifice (day 31 for three of the tumors and day 17 for the fourth ).
Apoptosis increases after transduction of p53, AS CD1, and a combination of both
Four to six replicates of each treatment were carried out and analyzed 1 -5 days after transduction with the optimal titer of 50 pfu / cell, as determined by [ 3 H ]thymidine incorporation.
Therapy using increased pfu / cell. We previously reported an increased rate of apoptosis after treatment of 451 cells with p53 (P < .0001 ) 17 or AS CD1 (P < .0001 ) 19 when compared to treatment with LacZ. Treatment with wt p53 or AS CD1 was equally effective. Doubling the dose of either treatment ( wt p53+ wt p53 or AS CD1 + AS CD1 ) did not affect the apoptotic response in either cell line.
Combination therapy. When wt p53 and AS CD1 were combined, there was a significant increase in apoptosis when compared to any other treatment: LacZ +LacZ (P < .001 for both 451 and 1205 ), wt p53 +wt p53 (P < .001 for both lines), and AS CD1 +AS CD1 (1205: P= .002, 451: P <.001 ). 
Discussion
We previously demonstrated that the p53 gene status of melanoma cells, whether mutant or wild type, predicted the in vitro efficacy of overexpression of wt p53 using an adenoviral vector, 17 and that suppression of CD1 protein expression led to growth inhibition in vitro and in vivo. 19 Unfortunately, in no case did monotherapy lead to tumor resolution. To further evaluate the efficacy of these vectors, we first determined the effect of intratumoral therapy with wt p53 on preformed melanomas. Next, we assessed the potential of combination therapy with wt p53 and AS CD1 both short ( 14 days ) and longer term, presuming that combining two treatments that attack the tumor at different points in the cell cycle ( G 1 and G 2 ) may be more effective than monotherapy. Finally, we tested the potential benefit of either doubling the viral dose or repeat therapy. We found that, whereas sequential therapy did not improve the effectiveness of treatment, increasing the viral dose improved the efficacy of p53 but not AS CD1. Combination therapy was significantly more effective than single -agent therapy, even after insuring that the total dose of virus in these treatments was equivalent.
A number of investigators have evaluated the effect of gene transfer of AS CD1 in model systems other than melanoma. 27 -31 These reports document the efficacy of AS CD1 in decreasing cell growth and tumorigenicity. We used the adenovirus as a vehicle for cell entry because it does not have the theoretical risk of inducing cancer and is effective whether or not the cell is dividing. Protein production from a CMV-driven promoter reliably yields high protein production for maximal effect.
We observed greater growth inhibition with wt p53 in tumors formed from 451 than from 1205 cells, extending our earlier in vitro findings that the ability of wt p53 overexpression to induce cell cycle arrest and apoptosis was dependent on the p53 status of the cells. 17 When we investigated the mechanism by which this occurred, we observed that melanoma cells with wt p53 protein did not undergo dephosphorylation of Ser-376, which is required for p53 activation.
Our prior work demonstrated that AS CD1 led to significant in vitro growth suppression and in vivo shrinkage of melanomas compared with control virus, whereas wt p53 delayed tumor growth, but the tumors did not decrease in size. Increasing the dose of wt p53 in relation to tumor volume ( same dose of virus but smaller tumors, each < 125 mm 3 compared to a median size in the larger tumors of 312 mm
3 ) led to a longer delay in tumor growth. Combining AS CD1 + wt p53 provided an additive growth inhibitory effect, with 4 /7 tumors undetectable after 14 days, compared to 0/ 21 tumors treated with AS CD1 or wt p53 alone.
Others have shown that multiple administrations of wt p53 adenovirus are more effective than single -dose therapy in tumor reduction and increased study animal survival using tumors formed from Renca cells. 32 We did not find repeated therapy to be more effective than single therapy in suppressing melanoma growth after treatment with AS CD1 and /or wt p53. Although we are not sure of why there was no response with repeat treatment, it is our presumption that the remaining tumor cells were resistant. In the study that we cite, it is likely that the remaining tumor cells were not resistant, but instead likely survived the first treatment because they were not exposed to an adequate dose of virus.
Whereas CD1 is thought to act primarily at the G 1 /S transition, p53 has been shown to promote both G 1 and G 2 arrest. 12, 33 In a prior report we demonstrated that AS CD1 was effective in decreasing [ 3 H ]thymidine incorporation and promoting both apoptosis and tumor shrinkage. Nonetheless, apoptosis was not observed in all cells, and no tumors were completely obliterated. 19 In the present manuscript, we report that 451 and 1205 cells undergo a significant increase in their rate of apoptosis after combined therapy with wt p53 and AS CD1, leading to more than half of the tumors vanishing 2 weeks after treatment.
In prior reports we demonstrated that p53 17, 34 and AS CD1 18, 19 induced apoptosis in squamous carcinoma and melanoma cells. In vitro measurement of the sub -G 0 fraction using flow cytometry was highly associated with in vivo apoptosis measured by TUNEL staining. In the present manuscript, we report that 451 and 1205 cells undergo a significant increase in their rate of apoptosis after combined therapy with wt p53 and AS CD1, whereas doubling the dose of a single vector or repeated doses of the same vector did not have a similar effect.
Using a preclinical model of melanoma, we outline a strategy to increase treatment effectiveness through the combination of two individually proven gene therapy vectors thus optimizing tumor response. Previous reports have observed increased cell killing and sometimes fewer side effects by combining vectors in genetic anticancer therapy. 35 Wt p53 and AS CD1 treatment may also prove to be an appropriate adjunct to currently available therapy, for example, to shrink the melanoma making surgery safer, or to be used as an additional form of multimodality therapy that attacks the tumor in a unique way. Our studies also indicate that tumor phenotype, specifically wt versus mutant p53 status, can influence treatment response, suggesting that therapy could be optimized by characterizing the genetic makeup of the tumor.
